Sarepta Therapeutics Inc. | |
Stock Exchange | Frankfurt Stock Exchange |
EPS |
- |
Market Cap |
- |
Shares Outstanding |
66.44 M |
Public Float |
53.91 M |
Sarepta Therapeutics Inc. | |
Stock Exchange | NASDAQ Stock Market |
EPS |
$5.94 |
Market Cap |
$11.18 B |
Shares Outstanding |
74.15 M |
Public Float |
66.53 M |
Address |
215 First Street Cambridge Massachusetts 02142 United States |
Employees | - |
Website | http://www.sareptatherapeutics.com |
Updated | 07/08/2019 |
Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare neuromuscular diseases. It focuses on the development of its potentially disease-modifying Duchenne Muscular Dystrophy drug candidates. The company was founded on July 22, 1980 and is headquartered in Cambridge, MA. |